IPCALAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | IPCALAB | Market Cap | 40,308 Cr. | Current Price | 1,598 ₹ | High / Low | 1,679 ₹ |
| Stock P/E | 40.1 | Book Value | 292 ₹ | Dividend Yield | 0.25 % | ROCE | 17.3 % |
| ROE | 12.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,538 ₹ | DMA 200 | 1,468 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 57.9 | MACD | 31.7 | Volume | 1,36,228 | Avg Vol 1Wk | 3,34,779 |
| Low price | 1,252 ₹ | High price | 1,679 ₹ | PEG Ratio | -31.4 | Debt to equity | 0.11 |
| 52w Index | 81.0 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 30.5 |
📊 Core Financials: Ipca Laboratories (IPCALAB) shows moderate fundamentals. ROCE at 17.3% and ROE at 12.4% indicate average capital efficiency. Debt-to-equity ratio of 0.11 reflects low leverage. Quarterly PAT of ₹303 Cr. is stable compared to ₹305 Cr. in the previous quarter, suggesting flat growth. EPS of ₹31.7 supports earnings consistency but not strong expansion.
💰 Valuation Indicators: Current P/E of 40.1 is above the industry average of 30.5, suggesting overvaluation. P/B ratio of ~5.5 (1598/292) indicates premium pricing. PEG ratio of -31.4 highlights weak growth prospects relative to valuation. Dividend yield of 0.25% provides minimal income return. Intrinsic value appears lower than current price, requiring cautious entry.
🏢 Business Model & Competitive Advantage: Ipca Laboratories operates in pharmaceuticals with a diversified portfolio across generics, APIs, and formulations. Its competitive advantage lies in established presence and global reach. However, profitability growth remains limited, and valuations are stretched compared to peers.
📈 Entry Zone: RSI at 57.9 suggests neutral-to-slightly overbought momentum, while MACD positive indicates bullish trend. Current price of ₹1,598 is near resistance (~₹1,679). Entry between ₹1,450–₹1,500 may be favorable for long-term investors seeking value.
⏳ Long-Term Holding Guidance: While Ipca Laboratories benefits from industry demand and low debt, high valuation and limited growth prospects make it suitable only for cautious long-term investors. Accumulation near lower support levels is recommended.
Positive
- 🌟 Low debt-to-equity ratio (0.11)
- 🌟 Stable quarterly PAT (₹305 Cr. → ₹303 Cr.)
- 🌟 Strong industry positioning in pharmaceuticals
Limitation
- ⚠️ High P/E (40.1) compared to industry average (30.5)
- ⚠️ PEG ratio of -31.4 indicates poor growth valuation
- ⚠️ Dividend yield of 0.25% is minimal
- ⚠️ ROE (12.4%) and ROCE (17.3%) are moderate
Company Negative News
- 📉 Flat quarterly profit growth
- 📉 Valuation concerns due to high P/E
Company Positive News
- 📈 Increase in DII holding (+0.14%)
- 📈 Stable earnings despite industry volatility
Industry
- 🌐 Pharmaceutical industry enjoys strong demand globally
- 🌐 Industry P/E at 30.5 reflects growth premium
- 🌐 Competition from peers with stronger growth metrics
Conclusion
✅ Ipca Laboratories shows stable fundamentals and low debt but is currently overvalued with limited growth prospects. Entry between ₹1,450–₹1,500 is favorable for cautious long-term investors. While industry demand supports resilience, valuations remain stretched, requiring careful accumulation.
Would you like me to also compare Ipca Laboratories with peers like Sun Pharma, Cipla, or Dr. Reddy’s to highlight relative strengths in the pharma sector?